UAE Human Insulin Market to grow at a CAGR of 3.01% to 2031
The expansion of healthcare infrastructure and a supportive
regulatory environment are the major drivers of the UAE Human Insulin
Market.
According to TechSci Research report, “UAE Human
Insulin Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2021-2031F”, the UAE Human Insulin Market will grow
from USD 48.11 Million in 2025 to USD 57.48 Million by 2031 at a 3.01%
CAGR. This may be due to collaborations and partnerships among leading
companies, which merge individual companies' expertise and strengthen their
positions.
Enhanced awareness encourages individuals to seek medical
attention for diabetes-related symptoms. Early diagnosis allows for timely
initiation of appropriate treatment, and in many cases, insulin therapy is a
vital component of diabetes management. Education initiatives help individuals
understand the role of insulin in regulating blood glucose levels. This
knowledge is essential for people with diabetes, healthcare professionals, and
the public in recognizing the significance of insulin therapy in diabetes care.
Awareness campaigns emphasize the importance of adherence to
prescribed treatment plans. For individuals with diabetes, this includes
adhering to medication regimens, monitoring blood glucose levels, and using
insulin therapy as needed to maintain optimal control. Education helps dispel
myths and reduce stigma associated with diabetes and insulin use.
Misconceptions and fear surrounding insulin therapy can be addressed through
accurate information, promoting greater acceptance and willingness to initiate
treatment. Increased awareness empowers individuals to participate in their
diabetes management actively. Patients who are well-informed about the benefits
and importance of insulin therapy are more likely to collaborate with
healthcare providers, leading to better treatment outcomes.
Browse over XX market data Figures and spread through XX
Pages and an in-depth TOC on " UAE Human Insulin Market.”
In April 2022, NeoBiocon, a collaboration between Biocon
Ltd, a leading biopharmaceutical company in Asia, and Dr. B.R. Shetty, Chairman
of Neopharma in the UAE, has announced a strategic partnership with Novartis
Middle East FZE. The collaboration aims to market Jalra (Vildagliptin) and
Jalra-M (Vildagliptin + Metformin) in the United Arab Emirates (UAE). This
venture is set to enhance NeoBiocon's product portfolio in the metabolics
segment, offering significant benefits to individuals with diabetes in the UAE.
Vildagliptin, an oral anti-diabetic agent, provides consistent and robust blood
sugar control for patients with type 2 diabetes. As a class of dipeptidyl
peptidase IV (DPP-IV) inhibitors, it is known for its weight-neutral effects
and a low risk of hypoglycemia. NeoBiocon has secured approvals from the
Ministry of Health, UAE, for the marketing of Jalra and Jalra-M in the country,
with launch scheduled for January 2016.
Many pharmaceutical companies source raw materials or
components globally. Disruptions in the supply chain, such as transportation
issues, customs delays, or manufacturing challenges in other countries, can
impact the availability of insulin products in the UAE. Transportation and
logistics are critical components of the pharmaceutical supply chain. Delays in
shipping, customs clearance, or transportation issues can affect the timely
delivery of insulin products to distributors and pharmacies in the UAE. Insulin
products have specific storage and handling requirements to maintain their
efficacy. Disruptions in temperature-controlled storage facilities or
noncompliance with proper handling practices can compromise the quality of
insulin products. Events such as pandemics, natural disasters, or other global
health emergencies can disrupt supply chains and impact the production,
distribution, and transportation of pharmaceutical products, including
insulin. Changes in trade regulations, tariffs, or other geopolitical
factors can affect the flow of goods across borders. This can impact the
importation of insulin products into the UAE and contribute to supply chain
disruptions.
UAE Human Insulin Market is segmented based on
Indication, Route of Administration, Type, Onset Time, Products, and by
region.
Based on the Type, UAE Human Insulin Market is
segmented into Basal, Bolus, Pre-mixed, Biosimilar, Traditional. A biosimilar
to human insulin is a biological product that is highly similar to an
already-approved reference or originator insulin. Biosimilars are not identical
copies of the reference product but are similar in quality, safety, and
efficacy. They are developed to be comparable alternatives to existing biologic
drugs, offering a more cost-effective option while maintaining therapeutic effectiveness. Unlike
traditional chemical drugs, which are typically synthesized through chemical
processes, biological products, including insulin, are complex molecules
produced in living cells using biotechnological methods. Biosimilar insulins
are designed to have a highly similar structure to reference insulin. This
similarity is established through rigorous analytical and functional
comparisons, demonstrating that the biosimilar is comparable to the reference
product in terms of safety and efficacy.
Based on Region, Abu Dhabi region held the largest
share in the UAE Human Insulin Market. The presence of research and
development centers focused on diabetes and related healthcare in Abu Dhabi
might attract pharmaceutical companies and contribute to advancements in
insulin products, giving the region a competitive edge. Well-established
distribution networks and logistical advantages in Abu Dhabi can facilitate the
efficient supply and distribution of insulin products, making it a preferred
location for market dominance. Abu Dhabi has specific healthcare policies and
regulations that create a conducive environment for pharmaceutical companies,
which could lead to the concentration of market activity in the region.
Some of the major companies operating in the UAE
Human Insulin Market include:
- Novo
Nordisk Pharma Gulf FZ-LLC
- Eli
Lilly and Company UAE
- Sanofi
UAE
- Baxter
International UAE
- B.
Braun Medical Gulf FZ-LLC
- Becton
Dickinson and Company UAE
- Gulf
Pharmaceutical Industries P.S.C.
- Biocon
Ltd
- Wockhardt
Ltd
- MannKind
Corporation
Download free Sample Report
Customers can also request 10% free customization on
this report.
“Certain areas, particularly in Dubai, are projected to
exert significant demand for Human Insulin. The growth in the competitive
landscape and the presence of well-established companies in the market,
committed to enhance the overall wellbeing of people each year, are expected to
contribute to a remarkable growth of the UAE Human Insulin Market in the
forecast period," said Mr. Karan Chechi, Research Director with TechSci
Research, a research-based Global management consulting firm.
UAE Human Insulin Market By Indication (Type I Diabetes,
Type II Diabetes), By Route of Administration (Subcutaneous, Nasal,
Intravenous, Transdermal, Oral and Others), By Type (Basal, Bolus, Pre-mixed,
Biosimilar, Traditional), By Onset Time (Rapid Acting, Short-Acting,
Intermediate Acting, Long Acting, Ultra-long Acting, Pre-Mixed, Inhaled), By
Products (Insulin Pens, Insulin Pumps, Infusion System, Injection), By Region,
Competition Forecast & Opportunities, 2021-2031F has evaluated
the future growth potential of UAE Human Insulin Market and provides statistics
& information on market size, structure, and future market growth. The
report aims to provide innovative market intelligence and help decision-makers
make sound investment decisions. Besides, the report also identifies and
analyzes the emerging trends along with essential drivers, challenges, and
opportunities in UAE Human Insulin Market.
Contact
Mr. Ken Mathews
Techsci Research LLC
420 Lexington Avenue, Suite 300, New York, United States-
10170
M: +13322586602
Email: [email protected]